Shire PLC (NASDAQ:SHPG) has earned a consensus rating of “Buy” from the twenty-five brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $220.91.
A number of research analysts have recently issued reports on the company. Cowen and Company reiterated an “outperform” rating and set a $325.00 target price on shares of Shire PLC in a research report on Wednesday, May 31st. Cantor Fitzgerald set a $222.00 target price on Shire PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price objective on shares of Shire PLC in a report on Wednesday, July 12th. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a report on Friday, June 16th. Finally, ValuEngine lowered Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd.
Several large investors have recently modified their holdings of the stock. Maverick Capital Ltd. increased its position in shares of Shire PLC by 19.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,942,087 shares of the biopharmaceutical company’s stock worth $320,969,000 after purchasing an additional 322,610 shares during the last quarter. Glenview Capital Management LLC increased its position in shares of Shire PLC by 69.7% during the 2nd quarter. Glenview Capital Management LLC now owns 1,722,977 shares of the biopharmaceutical company’s stock worth $284,756,000 after purchasing an additional 707,500 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Shire PLC by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock worth $268,773,000 after purchasing an additional 13,665 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Shire PLC by 14.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,510,227 shares of the biopharmaceutical company’s stock worth $249,577,000 after purchasing an additional 194,059 shares during the last quarter. Finally, BlackRock Inc. increased its position in shares of Shire PLC by 4,217.7% during the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock worth $249,755,000 after purchasing an additional 1,400,275 shares during the last quarter. 19.13% of the stock is owned by hedge funds and other institutional investors.
Shares of Shire PLC (NASDAQ SHPG) traded up 0.51% during midday trading on Tuesday, reaching $162.49. 748,675 shares of the company traded hands. The stock has a 50 day moving average price of $154.07 and a 200 day moving average price of $169.33. The firm has a market capitalization of $48.40 billion, a PE ratio of 72.70 and a beta of 1.61. Shire PLC has a 1-year low of $139.36 and a 1-year high of $209.22.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Analysts expect that Shire PLC will post $14.93 earnings per share for the current fiscal year.
The firm also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be given a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s payout ratio is 41.07%.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.